spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

YHEC announced appointment of Stuart Mealing as Associate Director of Health Technology Assessment

YHEC

Stuart Mealing Appointed Associate Director of Health Technology Assessment at YHEC

YHEC is pleased to announce the appointment of Stuart Mealing as Associate Director of Health Technology Assessment. Stuart will be leading the YHEC economic evaluation and modelling team. Stuart has a Masterís degree in operational research from the University of Lancaster Business School and a post-graduate certificate in international business management from Smurfit Business School, Dublin.

Stuart has worked in numerous therapy areas including oncology (solid tumour and haematological), cardiology, pulmonology, ophthalmology and neurology. Stuart has extensive experience in the development and review of cost-effectiveness and budget impact models, and has particular experience in working with medical devices and the modelling of orphan/ultra-orphan conditions.

Before joining YHEC in August 2017, Stuart was the EU Head of Health Economics at ICON Clinical Research Ltd and, before that, worked as a researcher at PenTAG, one of the research groups that performs independent assessments for NICE.

YHECís Director, Matthew Taylor, said:

ďIím delighted that Stuart has joined our team. He has spent over a decade working on NICE submissions and has a rich wealth of experience to share with our clients. His knowledge of economic evaluation will be an asset to the group, and the staff here are very much looking forward to working with him.Ē
phone +44 (0)1904 323620
email andria.hanbury@york.ac.uk
web www.yhec.co.uk/
email Address: YHEC, Enterprise House, Innovation Way, University of York, York, YO10 5NQ, United Kingdom
 
Print this page
Send to a friend
   
spacer
News and Press Releases

Fifth Annual Peptides Congress: Registration Now Open

Join us at the forefront of industry innovation at the 5th Annual Peptides Congress, 16-17 April 2018 in London to shape the future of industry discussion. With over 700 peptides in clinical trials and an increasing industry focus on biologics, now more than ever is the time to focus on this revolutionary field!
More info >>


White Papers

Autoinjectors From Planning to Launch

SHL Group

Looking at the rising trend towards self-administration therapies, injectable drug delivery devices such as pen injectors, autoinjectors and needle free injectors show a significant growth potential in the near future. In 2010, the pen systems and autoinjectors market was estimated to be worth over $0.58bn, a growth of 8-10% from previous years. It is estimated that the market will continue to grow steadily between 10-15% over the forecast period. It will reach $0.87bn in 2013 and $1.07bn in 2015. (Visiongain, June, 2011)
More info >>

Industry Events

5th Biennial Biosimilars & Biobetters Congress 2018

16-17 April 2018, Novotel London West Hotel, Hammersmith, London

Oxford Global are proud to present our highly anticipated 5thBiennial Biosimilars & Biobetters Congress, 16th Ė 17thApril 2018, London, UK. Over 450 proteins, peptides and biosimilars delegates representing leading biotech companies, global pharmaceutical organisations and internationally renowned academic institutions will enjoy over 20 presentations and case studies focusing on the key areas of the biosimilars industry including market access strategies, clinical development, commercialisation, manufacturing and bio-analytics
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement